| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2018 | ALLOVIR, INC. | 139 MAIN ST STE 500 | CAMBRIDGE | MA | 02142-1530 | MIDDLESEX | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 000 | 3 | FDA | 4/27/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | ALLOVIR, INC. | 139 MAIN ST STE 500 | CAMBRIDGE | MA | 02142-1530 | MIDDLESEX | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 000 | 8 | NIH | 10/28/2021 | $0 |
| | 2022 | 2019 | ALLOVIR, INC. | 139 MAIN ST STE 500 | CAMBRIDGE | MA | 02142-1530 | MIDDLESEX | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 001 | 8 | NIH | 11/4/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2018 | ALLOVIR, INC. | 139 MAIN ST STE 500 | CAMBRIDGE | MA | 02142-1530 | MIDDLESEX | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 000 | 3 | FDA | 3/24/2021 | $0 |
| | 2021 | 2018 | ALLOVIR, INC. | 2925 RICHMOND AVE STE 1274 | HOUSTON | TX | 77098-3130 | HARRIS | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 001 | 3 | FDA | 3/25/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | ALLOVIR, INC. | 2925 RICHMOND AVE STE 1274 | HOUSTON | TX | 77098-3130 | HARRIS | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 000 | 8 | NIH | 4/28/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,022,567 ) |
| | 2019 | 2019 | VIRACYTE, INC. | 2925 RICHMOND AVE STE 1274 | HOUSTON | TX | 77098-3130 | HARRIS | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 000 | 8 | NIH | 3/11/2019 | $1,022,567 |
|
| Issue Date FY: 2018 ( Subtotal = $1,053,343 ) |
| | 2018 | 2018 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 001 | 7 | NIH | 7/19/2018 | $0 |
| | 2018 | 2018 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 000 | 3 | FDA | 2/20/2018 | $249,697 |
| | 2018 | 2018 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 001 | 3 | FDA | 8/30/2018 | -$183,123 |
| | 2018 | 2018 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 000 | 7 | NIH | 4/1/2018 | $986,769 |
|
| Issue Date FY: 2017 ( Subtotal = $1,238,540 ) |
| | 2017 | 2017 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R44HL132348 | Path to Commercialization of the first ?off the shelf? T cell product | 000 | 6 | NIH | 6/12/2017 | $988,677 |
| | 2017 | 2016 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 002 | 2 | FDA | 8/10/2017 | $0 |
| | 2017 | 2016 | VIRACYTE, LLC | 33 5TH AVE NW STE 800 | NEW BRIGHTON | MN | 55112-3251 | RAMSEY | USA | R01FD005406 | Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014) | 001 | 2 | FDA | 1/27/2017 | $249,863 |
|
|
